Evidence mapPaperPMID 41424006Full record

ReviewBiomolecules & therapeutics2026

Gene Editing of Pluripotent Stem Cell-Derived Hepatic Cells for Liver Disease Modeling and Therapeutic Development.

Donghyun Lim, Hyung-Ryong Kim

Abstract readReview
In one paragraph

Review in Biomolecules & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Donghyun LimDepartment of Bioengineering, College of Engineering, and BK21 FOUR Education and Research Group for Biopharmaceutical Innovation Leader, Hanyang University, Seoul 04763, Republic of Korea.
Hyung-Ryong KimDepartment of Pharmacology, College of Dentistry, Jeonbuk National University, Jeonju 54896, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The growing demand for physiologically relevant human liver models has driven significant progress in generating hepatic cells and organoids derived from pluripotent stem cells. These regenerative cell sources serve as powerful platforms for elucidating the mechanisms underlying liver diseases and for evaluating drug responses under human-relevant conditions. Moreover, they hold tremendous promise as cell-based therapeutics for various hepatic disorders. The utility of these regenerative cell technologies is further expanded when combined with gene-editing techniques, which enable precise modeling of pathogenic variants and targeted correction of disease-associated mutations. Gene editing can also be leveraged to enhance the functionality and therapeutic potential of regenerative hepatocyte products. In this review, we summarize recent advances at the interface of gene editing and hepatic cell regeneration, emphasizing their applications in genetic disease modeling, therapeutic gene correction, drug testing, and cell-based therapies for liver disorders. We also provide an overview of major gene-editing tools and practical guidance for implementing them in pluripotent stem cells-based regenerative workflows, concluding with future perspectives on the integration of gene editing and regenerative hepatocyte technologies.

Indexed as

CRISPRGene editingHepatic cellsOrganoidsPluripotent stem cells

Identifiers

PMID41424006
PMCPMC12782869

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.